3 days popular7 days popular1 month popular3 months popular

Potential new treatment for two major eye diseases using tiny needles

Needles almost too small to be seen with the unaided eye could be the basis for new treatment options for two of the world’s leading : glaucoma and corneal neovascularization.

[Hypodermic-Microneedle Comparison]
In this image, a microneedle used to inject glaucoma medications into the eye is shown next to a conventional hypodermic needle.
Credit: Georgia Tech Photo: Gary Meek


Yoo , , and hold microneedle patents, and and Henry Edelhauser have significant financial interest in Clearside Biomedical, a company developing microneedle-based products for ocular delivery. This potential conflict of interest has been disclosed and is overseen by Georgia Institute of Technology and Emory University.

CITATIONS: Yoo C. Kim, Henry F. Edelhauser and Mark R. Prausnitz, “Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles,” (Investigative Ophthalmology & Visual Science, 2014) and Yoo C. Kim, Hans E. Grossniklaus, Henry F. Edelhauser and Mark R. Prausnitz, “Intrastromal Delivery of Bevacizumab Using Microneedles to Treat Corneal Neovascularization,” (Investigative Ophthalmology & Visual Science, 2014).

Research reported in this news release was supported by the National Eye Institute of the National Institutes of Health under award numbers R01EY022097 and R24EY017045. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Georgia Institute of Technology